Klarna has fallen roughly 75% from its post-IPO high, yet revenue rose 27%, transaction margin dollars surged 42%, and co-founder/CEO Sebastian Siemiatkowski just bought $9.95 million of KLAR. Is Wall Street pricing a broken fintech—or overlooking a rapidly evolving payments platform?

Read entire article

DICK’S Sporting Goods plunged roughly 30% as Foot Locker weakness rattled Wall Street. Then three directors bought $2.94 million. With core DICK’S comps up 4.9%, operating cash flow at $792 million and the stock at 9.3x forward earnings, is Wall Street pricing temporary integration pain like permanent deterioration?

Read entire article

NGL Energy Partners director John Raymond just put $5.1 million behind the turnaround. With record Permian water volumes, rising EBITDA and heavy institutional ownership, NGL looks increasingly compelling—but leverage keeps our FunStock Index at 7.95/10.

Read entire article

After falling roughly 46% from its all-time high, Tractor Supply has become one of retail's more intriguing turnaround candidates. CEO Hal Lawton recently invested more than $500,000 of his own money while institutions continue to own over 95% of the company. We examine whether today's valuation reset represents genuine opportunity—or simply reflects slowing fundamentals that still need to improve.

Read entire article

Pfizer has spent years under pressure following the collapse of pandemic-era revenues. Yet beneath the headlines, the company's non-COVID business is strengthening, oncology is expanding through Seagen, and two highly respected directors—including former Vanguard CEO and CIO Tim Buckley—recently invested nearly $2 million of their own money. We examine whether Wall Street is overlooking one of healthcare's most compelling value opportunities.

Read entire article

SiteOne Landscape Supply isn't flashy—but it may be one of the market's most overlooked industrial compounders. After a sharp correction, CEO Doug Black invested more than $816,000 of his own money while institutions continue to dominate the shareholder base. We examine the valuation, competitive moat, earnings, risks, and whether this roll-up story deserves another look.

Read entire article

Boston Scientific's stock has been cut nearly in half from its peak, yet the business remains fundamentally strong. With CEO Mike Mahoney buying $9 million worth of shares, a remarkably low 0.71 PEG ratio, billions in annual free cash flow, and overwhelming institutional ownership, is Wall Street overlooking one of healthcare's most attractive GARP opportunities?

Read entire article

Ionis Pharmaceuticals (NASDAQ: IONS) lost billions in market value after a disappointing clinical trial—but one director immediately bought more than $1 million worth of shares. Is Wall Street missing the bigger RNA platform story? Here's the full analysis.

Read entire article

Hudson Technologies isn't the hottest stock on Wall Street—but it may be one of the coolest. After synchronized insider buying from management, directors and a major shareholder, we examine whether this overlooked refrigerant specialist deserves a closer look.

Read entire article

Conagra's 50% dividend cut shocked income investors—but the story didn't end there. With CEO John Brase buying more than $510,000 of stock, debt moving lower, and shares trading around 10x forward earnings, the turnaround thesis deserves another look.

Read entire article